Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
about
Voriconazole therapeutic drug monitoring.Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Voriconazole pharmacokinetics in liver transplant recipients.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosisSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyCyclodextrin-based pharmaceutics: past, present and future.Inflammation is associated with voriconazole trough concentrations.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsComparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsPharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjectsIn vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.Pharmacokinetics of antifungal agents in children.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleInvasive fungal infections in acute leukemia.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.Antifungal therapeutic drug monitoring: established and emerging indications.New and investigational triazole agents for the treatment of invasive fungal infections.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazolePharmacogenomics of the triazole antifungal agent voriconazole.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomesImpact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients.Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosisEfficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
P2860
Q24542411-E21A5F65-1503-464A-B688-054ED112971BQ33257899-A89EBAEF-6F58-4573-BD36-F8253828197CQ33392206-43ECE6B4-216E-4218-99DB-15354B53B31AQ33613685-745CA184-0FCC-42E3-B37D-801F3503D0ABQ34045383-8B38831B-2867-41D1-8BBA-9D2C3A472CD0Q34138276-ECA626B4-A91B-40A5-A1BC-26B68F4AD537Q34290034-3C68E4FF-A35D-4680-81DD-12C1EBAF56ACQ34413393-48637E20-BC85-4EB5-8C8A-726889A6B914Q34552997-7727A78D-5004-4FB1-8F17-BA9B3233B16BQ34597394-EEF5DE23-8B89-40E4-AB80-002C764CCC7BQ35270270-E8B0A6CC-B5D8-41EB-9CF0-06358632261DQ35364006-5583F3B1-3225-43D7-8A6F-9F6D9B74C40EQ35635928-6DC660BD-CE50-4D7F-84BF-EAE5C2C2792DQ35647746-5E3AFA72-073A-43A4-A46E-FC465B8C5192Q35959476-0D33E5C3-035F-4096-9F7D-88B88B2595DDQ35973357-3CF5BAF3-706A-409D-AD71-4A08B579018FQ36024937-5241250E-67B0-4B16-AC01-941DD6283A0CQ36094896-C9C0FBFB-8B9F-4976-9EBF-C52E13BCD2DEQ36163345-74C28C76-5580-457F-AB6C-F1882C598E0BQ36521993-513C7930-6A40-4C12-B5B7-E8461D3A6A64Q36612597-66BB0157-194A-4D65-9404-184CC843A4A2Q36887922-77904F35-6F49-4948-A9DD-6954038BAF7DQ36927577-411B3C86-5B08-41B5-A01D-AD83F219C2D6Q37043539-63C1B03A-4494-4BF7-A530-7878D164E49CQ37263320-EC3541D2-91D8-4318-9E3D-C84E43877BCAQ37310029-066D9024-7D04-4B6B-A41A-382D7F3D8057Q37364295-DE795EE6-B3B5-4C5B-BDFB-9369E98CFAB5Q37471073-A9DBFD7A-7A2E-43DF-95F7-F304D21547B4Q37892536-C90EB374-014D-42DE-8C08-CBCB5C216153Q38193337-C1462BB6-0337-4477-8CAC-8569FE71DE82Q38284468-3F9356BA-1C0B-4576-BCC0-46BA73360DE8Q39932430-5E54DAC8-F81F-40CE-BF09-0733F3ADE98FQ40189236-662ADBA1-2E9B-4FAA-B80E-BD6888031608Q41962141-37959E63-51CE-41FA-892F-2CF390AE1B1CQ42180308-C72856A7-A4EE-4237-AC25-5D10072A8062Q42269872-51C42372-A413-4A9A-ADDF-BC3A06E7E16BQ42408726-F9F9DACB-3013-42B8-AAF6-960659CEB66EQ42623673-3530E38D-E03A-49DD-8A57-55CD1FC23A94Q42666741-FD3D4B7A-3C4E-489F-B6FC-0C4252C9AEC5Q44334907-E0F04AA5-FE2C-4F86-AD06-C118B8A75497
P2860
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@ast
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@en
type
label
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@ast
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@en
prefLabel
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@ast
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@en
P2093
P2860
P1476
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
@en
P2093
Katie Greenhalgh
Lynn Purkins
Michael J Allen
Nolan Wood
Stuart D Oliver
P2860
P356
10.1046/J.1365-2125.2003.01993.X
P407
P478
56 Suppl 1
P577
2003-12-01T00:00:00Z